Within this context, genetic deletion and epigenetic silencing would contribute to a downregulation of PHD3 in tumour progression, thereby decreasing the sensitivity to growth inhibitory signals and shifting the overall balance towards growth promotion. The gene discussed is EGLN3; the disease is neoplasm.